Navigation Links
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Date:2/27/2008

PALATINE, Ill., Feb. 27 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced that President and Chief Executive Officer Andy Reddick has begun a leave of absence for health reasons for an as-yet undetermined period. Mr. Reddick will continue to serve as a member of the Company's Board of Directors. At the same time, the Company announced that Richard Markham has been appointed to serve as non-executive Chairman of the Board. Mr. Markham has been a member of our Board of Directors since May, 2006. Since November 2004 Mr. Markham has served as a partner at Care Capital, LLC, a venture capital firm that primarily invests in life sciences companies. From May 2002 until August 2004, Mr. Markham was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA. From December 1999 until May 2002 he was the Chief Executive Officer of Aventis Pharma AG. Previously he was the Chief Executive Officer of Hoechst Marion Roussel, the President and Chief Operating Officer of Marion Merrell Dow, Inc. and a member of its board of directors. From 1973 to 1993 Mr. Markham was associated with Merck & Co. Inc., culminating in his position as President and Chief Operating Officer.

The Company's Board of Directors, management and staff all wish Mr. Reddick a full and speedy recovery and look forward to his return as soon as possible.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securi
'/>"/>

SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
2. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
3. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
4. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
11. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...e funds to move lab findings into human therapy fo...from nerve damage ,, ANN ARBOR, Mich., Nov. 9 ...versity of Michigan Department of Neurology have r...erapy for neuropathic pain, a difficult-to-treat c... of damage to nerve without obvious tissue injury....
(Date:11/9/2009)...e in French . , , Montreal, November 9, 2009...ale. In human bodies trillions of cells are couple...re composed. Yet these don,t come in twos, they a...use these complex cell networks are the backbone o... for ways to splice cell clusters down to their or...
(Date:11/9/2009)... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl...nounced the availability of INTUNIV (guanfacine) E...nited States for the treatment of Attention-Defici...olescents ages 6 to 17. INTUNIV, a once-daily for...cheduled alpha-2A receptor agonist approved for th...
(Date:11/9/2009)...ple around the world suffer from cataracts. Thomas...his coauthors discuss cataract surgery with the im...sue of Deutsches rzteblatt International ( Dtsch...ndness is usually due to opacification of the lens...rations are performed each year. Cataracts can be ...
(Date:11/9/2009)... people have tried to read Charles Darwin,s "Origi...0th anniversary this month, but gave up. , For t...k is about, help by way of a new book is at hand. ...eznick is the author of "The Origin Then and N...s " (Princeton University Press, 2009), which mak...
Breaking Medicine News(10 mins):Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2
...disorders among adolescent girls and boys can have...ead to dangerous weight-control behaviors, such as...t pills to control weight. The middle school age i... at the Harvard School of Public Health (HSPH) set...
...d number of youth with office visits with a diagno...tween 1994 and 2003, while adult visits with a bip... according to a report in the September issue of A...a (an abnormally elevated mood) and depression. Al...
... "Psoriasis Cure,Now," a nonprofit patient advoca... parents of children with psoriasis as their kids ...e fact sheet on children,s psoriasis,that parents ...discussing how to treat psoriasis in children and ...
...er 3 KFH has announced that it,has succeeded in o...SO,9001:2000 quality management systems with the B... Director, Dr Sally Sennitt, MD, says: "We are del...d,one that very few young medical device companies...
... data about the safety of drug-,eluting stents (DE...,patients with cardiovascular disease, according t...nterventions (SCAI). These new findings,also under...gimen of medications that prevent blood clots in t...
...fforts to control population growth in the present...s in the future. , This prediction comes from a S...r who spent a year in China studying its geriatric...niversity, said Chinas 1979 policy of limiting cou...
Other Medicine News:Health News:School-based overweight prevention program may cut risk of eating disorders among girls 2Health News:Study documents rapid increase in youth bipolar disorder diagnoses 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3
(Date:11/9/2009)...ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today...epreve(TM) (bepotastine besilate ophthalmic soluti...were presented in poster sessions at the 2009 Annu...hma & Immunology (ACAAI) in Miami Beach, FL. ...of Ocular Itching with Bepotastine Besilate Ophtha...
(Date:11/9/2009)...ll/ -- Arcadia Resources, Inc. (NYSE Amex: KAD ),...care services under the Arcadia HealthCare(SM) bra...f Directors. Goldsmith will replace Tres Lund who..., (Photo: http://www.newscom.com/cgi-bin/prnh/20...aul Professor of Government and Director of Innova...
(Date:11/9/2009)...ia/ -- Chindex International, Inc.,("Chindex") (Na...ider of Western,healthcare products and services i...results for the second quarter and first half of f... Financial Highlights:, -- Revenue in the seco...on, a year over year basis;, -- Net incom...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11Study of agricultural watersheds and carbon losses 8933 1Study of agricultural watersheds and carbon losses 8933 2Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 1Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 1Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 3
...euticals, Inc. (Nasdaq: ARNA ) announced today th...rial of APD125 in patients with primary,insomnia. ...na with the,potential to reduce insomnia symptoms ...hase 2b trial of APD125 is a double-blind, randomi...ng the efficacy and tolerability of,APD125 in pati...
...Navigenics, a,genetic health services company, tod... analysis. The Mayo Clinic study will examine how ...y a Navigenics genetic risk,assessment. The resear...etic assessments and the impact of such informatio...Proof of Principle Trial of Communication to,Patie...
Other Medicine Technology:Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 5Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 2
Wide Angle Twin MagNP Direct Ophthalmoscope
... the ultimate CT solution for cardiovascular and w... fastest multislice technology with dedicated clin...uality. It provides the highest performance, in or...ovascular diagnosis by utilizing innovative workfl...
...ceiling height, arm reach, power, cabling and the ...ity accommodates more gas, electric and communicat...nough for every surgical procedure and for emergen...lities, Teletoms are surprisingly easy to maneuver...
...fers you a complete solution to surgical lighting....b's original illumination to the surgical field an... field is clear and color correct with a 31" depth... 4500 Kelvin, giving you accurate tissue rendition...
Medicine Products: